Browsing Tag

22q

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at…

Eli Pacheco Sep 8, 2022 0

DEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for…

Health

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and…

Eli Pacheco Jan 5, 2022 0

– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference…